Vincerx Pharma, Inc. (VINC)
| Market Cap | 68.57K -59.7% |
| Revenue (ttm) | n/a |
| Net Income | -22.65M |
| EPS | -8.98 |
| Shares Out | 5.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 614 |
| Open | 0.0131 |
| Previous Close | n/a |
| Day's Range | 0.0131 - 0.0131 |
| 52-Week Range | 0.0002 - 0.0700 |
| Beta | 1.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Vincerx Pharma
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability. The company develops VIP943, an antibody drug conjugate in Phase 1 d... [Read more]
Financial Performance
Financial StatementsNews
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
Revised Potential Distribution Range of $0.03 to $0.07 per share based on current estimates and assumptions
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on July 16, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on July 7, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders Failure to approve Dissolution Proposal will reduce or eliminate any potential distribution...
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on June 18, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on June 6, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Quarterly report: Q1 2025
Vincerx Pharma has published its Q1 2025 quarterly earnings report on May 14, 2025.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on May 12, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on April 30, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global...
Vincerx Pharma Registration statement: Registration Filing
Vincerx Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.
Vincerx Pharma Annual report: Q4 2024
Vincerx Pharma has published its Q4 2024 annual report on March 27, 2025.
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings I...
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. f...
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on February 6, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on January 29, 2025, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma Registration statement: Registration Filing
Vincerx Pharma filed a registration statement on January 24, 2025, providing details about a securities offering with the SEC.
Vincerx Pharma, Inc. Announces Reverse Stock Split
Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on January 23, 2025, providing details for shareholder voting and corporate governance matters.
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma...
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjuga...
Vincerx Pharma Proxy statement: Proxy Filing
Vincerx Pharma filed a proxy statement on December 10, 2024, providing details for shareholder voting and corporate governance matters.
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943
Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts